<DOC>
	<DOCNO>NCT02631252</DOCNO>
	<brief_summary>This open label phase I clinical trial hydroxychloroquine ( HCQ ) , combine usual medication acute myeloid leukemia , mitoxantrone etoposide . The purpose study find safe effective dose hydroxychloroquine medication . The investigator test see increase effectiveness mitoxantrone etoposide .</brief_summary>
	<brief_title>Phase I Study Mitoxantrone Etoposide Combined With Hydroxychloroquine , Relapsed Acute Myelogenous Leukemia</brief_title>
	<detailed_description>Hydroxychloroquine FDA ( United States Food Drug Administration ) approve AML consider investigational drug study . It help make chemotherapy effective animal . The investigator test see increase effectiveness mitoxantrone etoposide . It combine type chemotherapy human types cancer . Most patient able take hydroxychloroquine safely dose studied clinical trial . Hydroxychloroquine approve FDA malaria , rheumatoid arthritis , autoimmune disease . Mitoxantrone approve FDA use AML , one common drug use treatment AML . Etoposide approve FDA AML . It approve small cell lung cancer testicular cancer . It commonly use AML . The primary objective trial determine recommend phase 2 dose ( RP2D ) HCQ combine mitoxantrone etoposide , secondary objective include efficacy estimate combination RP2D , safety tolerability profile combination , well correlation pharmacodynamic assessment autophagy inhibition dose clinical response .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Hydroxychloroquine</mesh_term>
	<criteria>1 . Able understand ability provide write consent 2 . Age &gt; 18 year old &lt; 80 year old 3 . Patients AML first morphologic relapse define &gt; 5 % reappearance leukemia blast bone marrow attributable cause ( Appendix I ) yet receive chemotherapy current relapse 4 . Eastern Cooperative Oncology Group Performance Status 0 2 ( see Appendix II ) 5 . Adequate organ function 1 . Serum creatinine ≤ 1.5 mg/dl calculate creatinine clearance ≥ 50 mL/min ( use CockcroftGault equation CL creatinine = ( 140age ) x body mass X 0.85 female ) /72 x creatinine age give year , body mass give kg creatinine give mg/dL ) 2 . Aspartate aminotransferase ( AST ) ≤ 5x upper limit normal Alanine aminotransferase ( ALT ) &lt; 5x upper limit normal 3 . Direct bilirubin ≤ 1.5 mg/dl Note : As many eligible patient pancytopenic secondary disease prior treatment , hematologic abnormality use criterion entry exclusion 6 . Left ventricular ejection fraction ( LVEF ) ≥50 % 7 . Females childbearing potential must negative pregnancy test screen subject must agree use effective method contraception . A woman eligible enter participate study : 1 . Nonchildbearing potential ( i.e. , physiologically incapable become pregnant ) include female hysterectomy bilateral oophorectomy ( ovariectomy ) . 2 . Childbearing potential , negative serum pregnancy test screen period agree avoid sexual activity use accept method contraception screen followup . Men female partner childbearing potential eligible enroll participate study either prior vasectomy agree avoid sexual activity use appropriate barrier contraception screen posttreatment followup . 1 . Acute promyelocytic leukemia 2 . Prior chemotherapy regimen give 1st relapse , include use hydroxyurea plasmapheresis use prior initiation chemotherapy . 3 . Previous use mitoxantrone etoposide combination therapy within precede 180 day screen . 4 . Symptomatic central nervous system ( CNS ) involvement 5 . Uncontrolled , lifethreatening infection respond antimicrobial therapy 6 . History psychiatric disorder may compromise compliance protocol allow appropriate inform consent 7 . Current receive anti neoplastic investigational agent 8 . Prior autologous allogeneic stem cell transplantation 9 . Concurrent malignancy . Exceptions : Patients diseasefree 5 year , subject history completely resect nonmelanoma skin cancer successfully treat situ carcinoma eligible . Subjects concurrent malignancy indolent definitely treat may enrol . 10 . Women pregnant breastfeed 11 . Evidence severe uncontrolled systemic disease ( e.g. , unstable uncompensated respiratory cardiac disease ) 12 . Inability take oral medication , due impair swallow ability poor absorption capacity 13 . Known glucose6phosphate dehydrogenase ( G6PD ) deficiency</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>Acute Myelogenous</keyword>
	<keyword>Phase I</keyword>
	<keyword>Mitoxantrone</keyword>
	<keyword>Etoposide</keyword>
	<keyword>Hydroxychloroquine</keyword>
	<keyword>Relapsed</keyword>
	<keyword>Autophagy inhibitor</keyword>
	<keyword>AML</keyword>
	<keyword>Relapsed AML</keyword>
</DOC>